Black-box warning imposed on Seattle Genetics' new lymphoma drug
This article was originally published in Scrip
Executive Summary
A black-box warning about the increased risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection, which can result in death, has been added to the labelling of Seattle Genetics' recently approved lymphoma drug Adcetris (brentuximab vedotin), an antibody-drug conjugate directed to CD30.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.